# Axbio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/axbio

- Industry: Biotechnology
- Headquarters: Santa Clara, US
- Website: www.axbio.com/
- Total disclosed funding: $100M
- Latest round: Series B (Jun 6, 2022)
- Investors on record: 5

## About

Axbio Inc. specializes in developing advanced technologies to enhance operational efficiency across various industries, including healthcare and manufacturing.Axbio Inc. was founded in 2016 and is headquartered in Santa Clara, US. The company focuses on creating innovative solutions that address complex operational challenges. In June 2022, Axbio raised USD 100 mn in Series B funding, co-led by YunFeng Capital and AstraZeneca, with additional investments from CBC Group, 5Y Capital, and SDIC Fund Management. The company does not operate under any parent company and does not have known subsidiaries. The founder has a strong entrepreneurial background, having previously launched successful ventures in the tech sector.Axbio Inc. provides innovative solutions tailored to meet the operational needs of diverse industries. Its core offerings include advanced technological tools designed to streamline business processes and enhance efficiency. The products specifically target challenges in sectors such as manufacturing, healthcare, and logistics, with initial launches in key markets across North America and Europe, and a growing presence in the Asia-Pacific region. The customer base consists mainly of medium to large enterprises focused on improving operational frameworks through technological advancements.Axbio Inc. generates revenue through direct sales and strategic partnerships within relevant industries, primarily on a subscription basis. This model allows clients to access the company's flagship products for a specified duration, fostering ongoing customer relationships and ensuring a stable revenue stream. The company also engages in B2B arrangements, distributing products to wholesalers and retailers. Pricing structures are designed to accommodate varying service levels, enhancing customer satisfaction and maintaining competitive positioning in the market.Axbio Inc. plans to utilize the USD 100 mn raised in June 2022 for the commercialization of its products. The company is actively designing and preparing to launch new products aimed at further addressing industry-specific challenges. Expansion efforts will focus on new markets, particularly in the Asia-Pacific region, targeting completion by the end of 2023. This strategic use of funding is integral to supporting product development and market entry initiatives.

## Funding rounds

- Series B, Jun 6, 2022, $100M — AstraZeneca, 5Y Capital, CBC Group, SDIC Fund Management, YunFeng Capital

## Investors

- AstraZeneca — Series B
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series B
- CBC Group (https://capitalatlas.ai/funds/cbc-group) — Series B
- SDIC Fund Management (https://capitalatlas.ai/funds/sdic-fund-management) — Series B
- YunFeng Capital — Series B